Inventiva S.A. (NASDAQ:IVA) Short Interest Up 12.6% in June

Inventiva S.A. (NASDAQ:IVA) was the target of a large increase in short interest in June. As of June 30th, there was short interest totalling 130,800 shares, an increase of 12.6% from the June 15th total of 116,200 shares. Based on an average trading volume of 15,000 shares, the short-interest ratio is currently 8.7 days.

Inventiva Stock Performance

Shares of IVA traded down $0.10 during trading hours on Wednesday, reaching $2.50. 3,405 shares of the company’s stock traded hands, compared to its average volume of 25,836. The firm’s 50 day simple moving average is $3.21 and its 200-day simple moving average is $3.56. Inventiva has a 12 month low of $2.47 and a 12 month high of $4.75.

Hedge Funds Weigh In On Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new position in Inventiva S.A. (NASDAQ:IVA) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,490 shares of the company’s stock, valued at approximately $38,000. 19.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Inventiva in a research report on Monday, April 1st. Canaccord Genuity Group raised their target price on Inventiva from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $17.00.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.